Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The median of procalcitonin, CRP, lactate, 25(OH)‐vitamin D, and cortisol within dead and living groups were 0.54 (0.2, 2.6) vs. 1.29 (0.2, 2.5) ng/mL; P = 0.510, 26 (15.6, 65) vs. 23.5 (14.3, 44.6) mg/L; P = 0.560, 2.8 (1.8, 5.3) vs. 2.33 (1.7, 2.8) mmol/L; P = 0.050, 20 (12, 32) vs. 22.07 (17, 29.2) mg/dL; P = 0.860, 18 (13.6, 24) vs. 17.15 (10.1, 22) μg/dL; P = 0.110, respectively (Table 1).

Source: Biochemical values. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A prospective cohort study was performed from December 2018 to December 2019.

Source: Abstract.

All consecutive hospitalized patients were screened and approached for enrollment by an internist and gastroenterologist at Phramongkutklao Hospital, Bangkok, Thailand.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Serum cystatin C as a predictor of 90‐day mortality among patients admitted with complications of cirrhosis

Cohort study · JGH Open: An Open Access Journal of Gastroenterology and Hepatology · 2021

Original publication title

Serum cystatin C as a predictor of 90‐day mortality among patients admitted with complications of cirrhosis

Anuchit Suksamai; Amnart Chaiprasert; Sakkarin Chirapongsathorn

© 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Serum Cys is superior to MELD score, and the new MELD‐Cys model is comparable to the MELD score in predicting mortality among patients with cirrhosis admitted with complications.

An extract from the source publication. Read it in context.

At a glance

Abstract: What methods does the paper describe?

A prospective cohort study was performed from December 2018 to December 2019. All cirrhotic patients admitted with acute decompensated liver cirrhosis or acute on chronic liver failure had laboratory values measured within 48 h of admission.

Source: Methods

Abstract: Background and Aim

Cystatin C (Cys) is not affected by age, sex, and muscle mass. We evaluated to compare the predictive performance of serum Cys level and model for end‐stage liver disease (MELD) score and developed a new model to predict 90‐day mortality among patients admitted with cirrhosis complications.

Source: Background and Aim

Abstract: Results

A cohort of 225 patients with cirrhosis was admitted during the study period. Sixty‐five patients were eligible for analysis. Twenty‐seven of these patients (41.4%) died within 90 days of follow‐up. The median of MELD score was 20.5 (15, 24). Serum Cys level of >1.45 mg/L had the highest 90‐day mortality prediction with the sensitivity and specificity of 66.7% and 68.4%, respectively. Cys and MELD scores were predictive of 90‐day mortality: Cys hazard ratio (HR) = 2.04 (95% CI 1.01 to 4.14, P = 0.048); MELD score HR = 1.01 (95% CI 0.51 to 2.01, P = 0.970).

C‐statistic of Cys, MELD score, model for end‐stage liver disease‐cystatin C (MELD‐Cys) score, combined Cys with MELD‐Cys score to predict 90‐day mortality were 0.67, 0.58, 0.58, and 0.63, respectively. Adding Cys to the MELD score did not improve the predictive of 90‐day mortality.

Source: Results

Abstract: Conclusion

Serum Cys is superior to MELD score, and the new MELD‐Cys model is comparable to the MELD score in predicting mortality among patients with cirrhosis admitted with complications.

Source: Conclusion
Authors’ abstract

Abstract

Background and Aim

Cystatin C (Cys) is not affected by age, sex, and muscle mass. We evaluated to compare the predictive performance of serum Cys level and model for end‐stage liver disease (MELD) score and developed a new model to predict 90‐day mortality among patients admitted with cirrhosis complications.

Methods

A prospective cohort study was performed from December 2018 to December 2019. All cirrhotic patients admitted with acute decompensated liver cirrhosis or acute on chronic liver failure had laboratory values measured within 48 h of admission.

Results

A cohort of 225 patients with cirrhosis was admitted during the study period. Sixty‐five patients were eligible for analysis. Twenty‐seven of these patients (41.4%) died within 90 days of follow‐up. The median of MELD score was 20.5 (15, 24). Serum Cys level of >1.45 mg/L had the highest 90‐day mortality prediction with the sensitivity and specificity of 66.7% and 68.4%, respectively. Cys and MELD scores were predictive of 90‐day mortality: Cys hazard ratio (HR) = 2.04 (95% CI 1.01 to 4.14, P = 0.048); MELD score HR = 1.01 (95% CI 0.51 to 2.01, P = 0.970).

C‐statistic of Cys, MELD score, model for end‐stage liver disease‐cystatin C (MELD‐Cys) score, combined Cys with MELD‐Cys score to predict 90‐day mortality were 0.67, 0.58, 0.58, and 0.63, respectively. Adding Cys to the MELD score did not improve the predictive of 90‐day mortality.

Conclusion

Serum Cys is superior to MELD score, and the new MELD‐Cys model is comparable to the MELD score in predicting mortality among patients with cirrhosis admitted with complications.

Publication and source details

Original title: Serum cystatin C as a predictor of 90‐day mortality among patients admitted with complications of cirrhosis

Anuchit Suksamai; Amnart Chaiprasert; Sakkarin Chirapongsathorn

JGH Open: An Open Access Journal of Gastroenterology and Hepatology · 2021

* Correspondence
*Sakkarin Chirapongsathorn, Division of Gastroenterology and Hepatology, Phramongkutklao Hospital, College of Medicine, 315 Ratchawithi Rd, Ratchathewi, Bangkok, Thailand 10400.
Email: sakkarin.chi@pcm.ac.th
© 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Department of medicine, Phramongkutklao hospital

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:06:06.717963+00:00

DOI: 10.1002/jgh3.12543 · PMC8114990